AIxCrypto Stock (AIXC.US) Real-time Quotes - Financial Data - Analyst Ratings

Company Encyclopedia

AIxCrypto

AIXC.US

AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was formerly known as Qualigen Therapeutics, Inc.

1.875 T

AIXC.USMarket value -Rank by Market Cap -/-

Valuation analysis

P/E

10Y

P/E

Industry Ranking

-/-

P/E
Price
High
Median
Low

P/B

10Y

P/B

Industry Ranking

-/-

P/B
Price
High
Median
Low

P/S

10Y

P/S

Industry Ranking

-/-

P/S
Price
High
Median
Low

Dividend Yield

10Y

Dividend Yield

Industry Ranking

-/-

Dividend Yield
Price
High
Median
Low

Institutional View & Shareholder

Analyst Ratings

Rating

Percentage

Price
--
Highest
--
Lowest
--

Shareholder

Ownership	%Owned	Share Chg	Report Date
Faraday Future Intelligent Electric Inc.	14.67%	No Change	06/11/2025
Alpha Capital Anstalt	9.06%	No Change	30/09/2025
Point72 Asset Management, L.P.	1.64%	No Change	30/09/2025
Geode Capital Management, LLC	0.31%	-133.00	30/09/2025
UBS Asset Management AG	0.19%	No Change	30/09/2025
BlackRock, Inc.	0.03%	-10.00	30/09/2025
The Vanguard Group, Inc.	0.03%	No Change	30/09/2025
Tower Research Capital Europe Limited	0.02%	-775.00	30/09/2025
Harbour Investments, Inc.	0.02%	No Change	30/09/2025
Stone House Investment Management, LLC	0.01%	No Change	30/09/2025

News

Qualigen Therapeutics Rebrands as AIxCrypto Holdings

Qualigen Therapeutics Inc. has rebranded as AIxCrypto Holdings, Inc. (Nasdaq: AIXC), focusing on integrating AI, crypto, and blockchain technologies to build a global digital ecosystem.

Reuters·Yesterday at 05:24

AIXC

-3.42%

Reuters·Yesterday at 05:24

AIXC

-3.42%

Faraday Future Intelligent Electric: AIxCrypto renamed and listed, dual listing structure completed

On November 21st, Faraday Future announced that its controlled and majority-owned NASDAQ-listed company Qualigen Therapeutics Inc. has officially completed its name change and is now named AIxCrypto Holdings Inc. (abbreviated as AIxC). The "dual listing" structure of FFAI and AIXC has been officially established. (Jiemian)

36Kr·Yesterday at 11:56

36Kr·Yesterday at 11:56

QLGN, a listed company in which Jia Yueting invested, has been renamed AIxCrypto and will launch a stock tokenization business.

Faraday Future announced that QLGN, a Nasdaq-listed company strategically invested in by FFAI, has changed its name to AIxCrypto (AIXC) and unveiled three new business lines. Among these, AIXC will launch a stock tokenization RWA business, with the first project being the tokenization of FFAI stock. The company plans to purchase $5 million worth of FFAI stock through an independent third party, helping Faraday Future secure Web3 funding at a lower cost than Web2 funding.

CoinLive·Yesterday at 09:15

AIXC

-3.42%

CoinLive·Yesterday at 09:15

AIXC

-3.42%

Faraday Future Completes Formation of “FFAI+AIXC” Dual-Flywheel, Dual-Bridge, and Dual-Listed Company System; Its Majority Owned Crypto Company Renamed as AIxCrypto (Nasdaq: AIXC) | FFAI Stock News

Faraday Future announced the completion of its dual-flywheel, dual-bridge, and dual-listed company system with the renaming of its majority-owned crypto company to AIxCrypto (Nasdaq: AIXC). This initiative aims to bridge Web2 and Web3, benefiting FFAI in financing, assets, technology, users, and valuation. AIxC plans to explore tokenizing up to $5 million of FFAI Class A common stock. The collaboration will advance EAI EV assets' on-chain registration and verification and develop integrated EAI + RWA products.

StockTitan·11/21/2025 07:21

StockTitan·11/21/2025 07:21